
FLOATING-HARBOR SYNDROME: PRESENTATION OF
THE FIRST ROMANIAN PATIENT WITH A SRCAP MUTATION
AND REVIEW OF THE LITERATURE Budisteanu M, Bögershausen N, Papuc SM, Moosa S, Thoenes M, Riga D, Arghir A, Wollnik B *Corresponding Author: Aurora Arghir, M.D., Ph.D., Victor Babes National Institute of Pathology, Medical Genetics Laboratory,
99-101 Splaiul Independentei, 050096 Bucharest, Romania. Tel/Fax: +40-21-319-27-32, ext. 207/+40-21-319-45-28.
E-mail: aurora.arghir@ivb.ro page: 83
|
INTRODUCTION
Floating-Harbor syndrome (FHS, MIM 136140) is
a rare genetic condition characterized by proportionate
short stature, delayed bone age, expressive language delay
and distinctive facial features [1]. The syndrome was first
described in two patients at the Boston Floating Hospital
[2] and at the Harbor General Hospital in Torrance, CA,
USA, respectively, hence the name [3]. Its prevalence is
unknown; if we take into account only SRCAP mutated
cases, around 65 individuals have been reported to date.
The FHS is caused by heterozygous mutations in
exons 34 [4-6] and 33 [7,8] of the SRCAP gene, on chromosome
16p11.2. The SRCAP gene mutations are de novo
truncating mutations. The SRCAP protein activates the
CREBBP gene that is involved in the regulation of cell
growth and division.
Growth deficiency in FHS becomes apparent in the
first year of life, but it can occur before birth. Affected children
have a short stature with an average height below the
5th percentile. Bone age is delayed in the first decade of life.
Typical facial features in patients with FHS include
a triangularly-shaped face, low-set ears, low hairline,
deep-set eyes with abnormally long eyelashes, a long,
triangular-shaped nose with a low hanging columella, a
short philtrum, and a broad, linear mouth with thin lips
[9]. Expressive language delay is a common feature,
varying from mild to very severe. Most affected children
show some degree of intellectual disability, ranging from
mild to severe; some patients have behavioral troubles
(hyperactivity, attention deficit, aggression, obsessive
behavior). Patients with FHS tend to have an unusually
high-pitched voice. Other symptoms reported in individuals
with FHS include skeletal anomalies (brachydactyly,
fifth finger clinodactyly, 11 pairs of ribs, kyphoscoliosis),
congenital heart malformations (aortic coarctation, atrial
septal defect, tetralogy of Fallot), gastrointestinal features
(motility problems, celiac disease), genitourinary abnormalities
(kidney agenesis, renal cysts, hydronephrosis,
precocious puberty, cryptorchidism, hypospadias), dental
anomalies (supernumerary teeth, microdontia, malocclusion, delayed loss of primary teeth), ear anomalies (recurrent
otitis media, conductive hearing loss), ophthalmologic
issues (hyperopia, refractive errors, strabismus), seizures
and hypothyroidism [9].
Here, we report on a patient with growth deficiency,
dysmorphic facial features, language delay, and mild intellectual
disability, with a known pathogenic mutation
c.7330C>T, p.(Arg2444*) in the SRCAP gene. To the best
of our knowledge, this is the first case of molecularly
proven FHS in Romania.
Clinical Report. A 7-year-old Romanian boy was
referred to the Pediatric Neurology Department, for speech
delay. The boy is the second child of healthy, unrelated
parents. The pregnancy was uncomplicated, fetal ultrasound
revealed short humerus (at 5 months of gestation).
The child was born at 40 weeks with a birth weight of
2800 g, 51 cm in length, and good postnatal adaptation.
The child presented normal motor development, but delayed
language development (he uttered first syllables at 27
months and first words at 4 years 6 months. Hypospadias
was diagnosed at birth and surgically corrected at 1 year;
the boy had frequent respiratory and middle ear infections.
In the first year of life, he presented feeding difficulties
and failure to thrive.
Clinical examination at 7 years old revealed: a height
of 107 cm [<2 standard deviation (SD), a weight of 17 kg
(<2 SD), an occipito-frontal circumference (OFC) of 50
cm (10th percentile). He had dysmorphic facial features: a
triangularly-shaped face, deep-set eyes, long eyelashes, lowset
malformed ears (hypoplastic helix, small ear lobe), a long
nose with narrow bridge, a short philtrum, thin lips, microdontia,
malocclusion, and a low frontal hairline (Figure 1).
He also had mild mental retardation (IQ 66), severe
expressive language delay (few simple sentences), hyperkinesia
and attention deficit, episodes of aggressiveness
at minor frustrations. Skeletal anomalies (brachydactyly,
broad finger tips) were noted at clinical investigation. Xray
examination showed a bone age of 3 years at the age
of 6. Cerebral magnetic resonance imaging (MRI) was
normal, including normal pituitary anatomy, as were heart
and abdominal ultrasound. Ophthalmologic evaluation was
also normal. The levels of thyroid and growth hormones
were within the normal range. Taking into account the
association of growth deficiency with delayed bone age,
expressive language delay and distinctive facial features, a
clinical diagnosis of FHS was established. Written consent
for publishing clinical data and images of the patient was
obtained from the parents.
Sanger sequencing of exons 33 and 34 of the SRCAP
gene identified the heterozygous mutation c.7330C>T
on exon 34. At the protein level, this sequence alteration
leads to truncation of the protein at position 2444
(p.Arg2444*). This mutation is reported in the databases
dbSNP (rs199469464; http://www.ncbi.nlm.nih.gov/
SNP/), Clin Var (RCV000023895; http://www.ncbi.nlm.
nih.gov/clin var/) and HGMD (https://portal.biobaseinternational.
com/ hgmd/pro/start.php) as a pathogenic
variant. Segregation analysis revealed that both parents
do not carry the mutation c.7330C>T, showing that it has
occurred de novo in the patient.
According to current recommendations, we instituted
an intensive program of cognitive and speech stimulation,
using picture exchange communication system (PECS),
and behavioral therapy. Yearly neurological, psychological,
ophthalmological, otorhinolaryngological, pediatric and
endocrinological, monitoring of our patient was planned.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|